昆明陆韩进出口有限公司

首页 > 新闻资讯 >

Mylan closes on oncology API plant as it rolls through India

February 21, 2013 -- Score another deal for Mylan ($MYL) as it methodically expands its manufacturing capabilities in India.
The U.S. generics company closed on its $32.5 million deal to buy a nearly-new, FDA-approved plant in India from SMS Pharmaceuticals, India's Moneycontrol reports. The plant in Vizag manufactures active pharmaceutical ingredients through finished oncology products, including injectable drugs. SMS brought the plant online in 2008. Mylan closed on that acquisition just a week after it said it would pay $30 million to pick up a manufacturing plant from India's Unichem Laboratories in the central part of the country.
And that came even as Mylan surfaced in reports by unnamed sources that it is in "exclusive talks" to buy Strides Arcolab's sterile injectable drug manufacturing business for as much as $2 billion. India's Strides has been shopping the business for months, and Pfizer ($PFE) and Novartis ($NVS) were previously mentioned as suitors. Mylan and Strides have been mum about a possible deal. 
关于陆韩

公司介绍

陆韩优势

研发技术

资质证书

产品系列

原料药

中间体和提取

开发中

制剂类

客户服务

技术服务

产品采购

留言反馈

联系我们

电话: +86 0871 6511 0906

传真:0871-63602606 (GMT+8 AM9:00-AM:12:00 PM1:30-PM6:00)

Email: info@luhancn.com

地址:云南省昆明市盘龙区北京路时尚家园B座3301